|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHRM2 |
Gene summary for CHRM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHRM2 | Gene ID | 1129 |
| Gene name | cholinergic receptor muscarinic 2 | |
| Gene Alias | HM2 | |
| Cytomap | 7q33 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A4D1Q0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1129 | CHRM2 | A015-C-203 | Human | Colorectum | FAP | 1.41e-06 | 5.50e-01 | -0.1294 |
| 1129 | CHRM2 | A002-C-116 | Human | Colorectum | FAP | 2.18e-13 | 6.14e-01 | -0.0452 |
| 1129 | CHRM2 | CRC-3-11773 | Human | Colorectum | CRC | 5.06e-08 | 5.79e-01 | 0.2564 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00902574 | Colorectum | FAP | regulation of muscle system process | 58/2622 | 252/18723 | 7.22e-05 | 1.33e-03 | 58 |
| GO:00030122 | Colorectum | FAP | muscle system process | 89/2622 | 452/18723 | 4.63e-04 | 5.39e-03 | 89 |
| GO:00069371 | Colorectum | FAP | regulation of muscle contraction | 37/2622 | 169/18723 | 3.39e-03 | 2.47e-02 | 37 |
| GO:00902575 | Colorectum | CRC | regulation of muscle system process | 51/2078 | 252/18723 | 1.49e-05 | 4.63e-04 | 51 |
| GO:00030123 | Colorectum | CRC | muscle system process | 74/2078 | 452/18723 | 3.92e-04 | 5.80e-03 | 74 |
| GO:00069372 | Colorectum | CRC | regulation of muscle contraction | 33/2078 | 169/18723 | 8.65e-04 | 1.07e-02 | 33 |
| GO:1903522 | Colorectum | CRC | regulation of blood circulation | 43/2078 | 256/18723 | 3.70e-03 | 3.12e-02 | 43 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa048106 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
| hsa04024 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
| hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa048107 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
| hsa040241 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
| hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
| hsa048108 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
| hsa040242 | Colorectum | CRC | cAMP signaling pathway | 47/1091 | 225/8465 | 4.57e-04 | 4.77e-03 | 3.23e-03 | 47 |
| hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa047252 | Colorectum | CRC | Cholinergic synapse | 24/1091 | 113/8465 | 8.58e-03 | 3.98e-02 | 2.70e-02 | 24 |
| hsa048109 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
| hsa040243 | Colorectum | CRC | cAMP signaling pathway | 47/1091 | 225/8465 | 4.57e-04 | 4.77e-03 | 3.23e-03 | 47 |
| hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
| hsa047253 | Colorectum | CRC | Cholinergic synapse | 24/1091 | 113/8465 | 8.58e-03 | 3.98e-02 | 2.70e-02 | 24 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHRM2 | SNV | Missense_Mutation | rs143842239 | c.169N>A | p.Val57Ile | p.V57I | P08172 | protein_coding | deleterious(0.03) | possibly_damaging(0.683) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| CHRM2 | SNV | Missense_Mutation | rs143842239 | c.169G>A | p.Val57Ile | p.V57I | P08172 | protein_coding | deleterious(0.03) | possibly_damaging(0.683) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHRM2 | SNV | Missense_Mutation | novel | c.997N>G | p.Lys333Glu | p.K333E | P08172 | protein_coding | tolerated(0.39) | benign(0.038) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHRM2 | SNV | Missense_Mutation | c.562T>A | p.Phe188Ile | p.F188I | P08172 | protein_coding | deleterious(0) | possibly_damaging(0.823) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHRM2 | SNV | Missense_Mutation | novel | c.1000N>G | p.Ser334Gly | p.S334G | P08172 | protein_coding | tolerated(0.62) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CHRM2 | SNV | Missense_Mutation | c.422N>T | p.Gly141Val | p.G141V | P08172 | protein_coding | deleterious(0.04) | possibly_damaging(0.542) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CHRM2 | SNV | Missense_Mutation | c.1034N>G | p.Glu345Gly | p.E345G | P08172 | protein_coding | tolerated(0.15) | benign(0.034) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| CHRM2 | SNV | Missense_Mutation | c.172A>T | p.Asn58Tyr | p.N58Y | P08172 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CHRM2 | deletion | Frame_Shift_Del | novel | c.889delN | p.Arg297GlufsTer5 | p.R297Efs*5 | P08172 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CHRM2 | SNV | Missense_Mutation | novel | c.585N>G | p.Phe195Leu | p.F195L | P08172 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | CHEMBL1133 | OXYBUTYNIN CHLORIDE | |
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | THIETHYLPERAZINE | THIETHYLPERAZINE | ||
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | CHEMBL2103803 | DAROTROPIUM BROMIDE | |
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | CHEMBL2146146 | ATROPINE SULFATE | |
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135651180 | ||
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | ACECLIDINE | ACECLIDINE | ||
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 178100307 | ||
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | ENDO-ATROPINE | ENDO-ATROPINE | 25051097 | |
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135649900 | OTENZEPAD | |
| 1129 | CHRM2 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 252166801 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |